Biotech News
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
xerispharma.com2026-05-06 15:00 EST
Total product revenue increased 40% YoY to $74 million Recorlev® revenue grew 109% YoY to $37 million Updating full-year 2025 total revenue guidance to $285-$290 million ; previously $280-$290 million Hosts conference call and webcast today at 8:30 a.m. ET CHICAGO --(BUSINESS WIRE)--Nov.